HIV IN
HIV integrase is a 32 kDa protein produced from the C-terminal portion of the Pol gene product, and is an attractive target for new anti-HIV drugs.
In November 2005, data from a phase 2 study of an investigational HIV integrase inhibitor, MK-0518, demonstrated that the compound has potent antiviral activity. On October 12, 2007, the Food and Drug Administration (U.S.) approved the integrase inhibitor Raltegravir (MK-0518, brand name Isentress TM). The second integrase inhibitor, elvitegravir, was approved in the U.S. in August 2012.
The crystal structure of human foamy virus integrase has been examined successfully.
This protein may use the morpheein model of allosteric regulation.
Read more about this topic: Integrase